Positive Quality Intervention: Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

**Description:** The purpose of this PQI is to discuss the clinical considerations of tafasitamab-cxix (Monjuvi®) to optimize the outcomes for patients with relapsed/refractory (R/R) diffuse large B-Cell lymphoma (DLBCL).

**Background:** DLBCL is an aggressive lymphoma and is the most common subtype of non-Hodgkin’s lymphoma (NHL) in the United States, accounting for approximately 25% of newly diagnosed B-Cell NHL cases each year.¹ The prognosis for patients with R/R disease remains poor, with expected survival of less than 8 months.² Tafasitamab-cxix is a CD19-directed cytolytic antibody as a preferred regimen indicated in combination with lenalidomide for the treatment of adult patients with R/R DLBCL who are not eligible for autologous stem cell transplant.³,⁴ It was approved under the FDA accelerated approval pathway based on overall response rate and confirmatory trials are currently underway. Efficacy of this regimen was based on the L-MIND study which was a multicenter, open-label, single arm, phase 2 study enrolling adult patients with R/R DLBCL after 1-3 prior systemic therapies, one of which being an anti-CD20 therapy.⁵ The primary endpoint of the study was objective response rate with key secondary endpoints being duration of response, progression-free survival, and overall survival. At a median follow-up of 13.2 months, 48 of the 80 enrolled patients (60%, 95% CI 48-71%) had an objective response with 34 patients (43%) achieving a complete response. An additional 11 patients (14%) had stable disease which equates to a disease control rate of 74%. The most common Grade ≥ 3 adverse events were neutropenia (48%), thrombocytopenia (17%), and febrile neutropenia (12%). A large phase 2/3 randomized trial, B-MIND, is underway to compare tafasitamab-cxix plus lenalidomide versus rituximab plus bendamustine in patients with R/R DLBCL.⁶

**PQI Process:** Upon the receipt of a new prescription of tafasitamab-cxix for R/R DLBCL

- **Verify pre-medications:** acetaminophen, H1 receptor antagonist, H2 receptor antagonist, and a corticosteroid should be given 30-120 minutes prior to the first 3 infusions (if no reaction occurs during the first 3 infusions, then optional with subsequent infusions)

- **Verify tafasitamab-cxix dosing**
  - Cycle 1: 12 mg/kg on days 1, 4, 8, 15, 22
  - Cycles 2-3: 12 mg/kg on days 1, 8, 15, 22
  - Cycle 4+: 12 mg/kg on days 1 and 15

- **Verify lenalidomide dosing:** 25 mg once daily on days 1-21 of a 28-day cycle for up to 12 cycles
  - Ensure all lenalidomide REMS requirements are met
  - Dose adjustments needed for baseline renal dysfunction

- **Monitoring**
  - CBC and CMP: baseline and prior to each treatment cycle
  - Consider granulocyte colony-stimulating factor administration (intermediate risk)

- **Preparation**
  - Tafasitamab-cxix is supplied as 200 mg vials
  - Reconstitute each 200 mg vial with 5 mL of sterile water (final concentration of 40 mg/mL)
  - Dilute to desired volume with 250 mL of 0.9% sodium chloride (final concentration of 2-8 mg/mL)
  - Store the diluted solution refrigerated for up to 18 hours followed by up to 12 hours at room temperature or at room temperature for up to 12 hours
  - Protect from light during storage

**IMPORTANT NOTICE:** NCODA has developed this Positive Quality Intervention platform. This platform is intended as an educational aid, does not provide individual medical advice, and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication. The materials contained in this platform do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA. NCODA does not ensure the accuracy of the information presented and assumes no liability relating to its accuracy. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. It is the individual’s sole responsibility to seek guidance from a qualified healthcare professional. Updated 9.27.23
• Administration
  o First infusion: administer intravenously at 70 mL/h for the first 30 minutes then increase the rate so that the infusion is administered over 1.5-2.5 hours
  o Subsequent infusions: administer over 1.5-2 hours
  o Do not co-administer other medications through the same infusion line as tafasitamab-cxix
• Adverse Event Management: see supplement section

Patient-Centered Activities:
• Provide written and verbal patient education
  o Review the most common adverse effects: neutropenia, fatigue, anemia, diarrhea, cough, thrombocytopenia, fever, peripheral edema, respiratory tract infection, and decreased appetite
  o Instruct patient to report any adverse events to the care team
• Patient Assistance: NCODA Financial Assistance Tool

References:
3. Monjuvi (tafasitamab) [prescribing information].
4. NCCN Guidelines Diffuse Large B-Cell Lymphoma.

Supplemental Information:
Adverse Reaction Management

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Severity</th>
<th>Dosage Modification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematologic toxicity</td>
<td>Platelets ≤ 50,000/mm³</td>
<td>Hold tafasitamab-cxix (and lenalidomide), monitor CBC weekly until platelet count is ≥50,000/mm³, then resume tafasitamab-cxix at the same dose (and lenalidomide at a reduced dose).</td>
</tr>
<tr>
<td></td>
<td>Neutrophil count ≤ 1,000/mcL for at least 7 days or neutrophil count ≤ 1,000/mcL with fever (temp ≥100.4°F or ≥38°C) or neutrophil count &lt; 500/mcL</td>
<td>Hold tafasitamab-cxix (and lenalidomide), monitor CBC weekly until neutrophil count is ≥1,000/mcL, then resume tafasitamab-cxix at the same dose (and lenalidomide at a reduced dose).</td>
</tr>
<tr>
<td>Infusion-related reaction</td>
<td>Grade 2 (moderate)</td>
<td>Interrupt infusion immediately and manage symptoms. Once resolved or reduced to Grade 1, resume infusion at 50% rate at which reaction occurred. If no further reaction within 1 hour and vital signs are stable, may increase infusion rate every 30 minutes as tolerated to rate at which the reaction occurred.</td>
</tr>
<tr>
<td></td>
<td>Grade 3 (severe)</td>
<td>Interrupt infusion immediately and manage symptoms. Once resolved or reduced to Grade 1, resume infusion at 25% rate at which reaction occurred. If no further reaction within 1 hour and vital signs are stable, may increase infusion rate every 30 minutes as tolerated to a maximum of 50% rate at which the reaction occurred. Stop immediately if reaction returns upon rechallenge.</td>
</tr>
<tr>
<td></td>
<td>Grade 4 (life threatening)</td>
<td>Stop infusion immediately and permanently discontinue.</td>
</tr>
</tbody>
</table>